Trasylol Public Health Advisory Cites Kidney, Heart Attack, Stroke Risks
FDA will convene an advisory committee meeting to discuss the risks and benefits of Bayer's transfusion-sparing agent following risk reports.
FDA will convene an advisory committee meeting to discuss the risks and benefits of Bayer's transfusion-sparing agent following risk reports.